Biopharma & Life Sciences
Kala Bio, Inc. Executive Compensation (FY25)
KALA · Executive and director compensation, fiscal 2022 to 2025
Latest say-on-pay support = June 11, 2024 |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Kala Bio, Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of October 28, 2026Latest filing (DEF 14A): September 24, 2026
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
175 figures on this page: 173 cited to the filing that reported them, 2 calculated from figures it prints. See the citations
More on Kala Bio, Inc.
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Mark Iwicki: $1,491,187 → $906,642 (39.2% lower)
Say-on-pay support: 89.6% → 77.2% (12.4 points lower)
Frequently asked questions
Answers drawn from the data on this page.
What was Kala Bio, Inc.'s say-on-pay result?
The say-on-pay proposal drew 77.2% of votes cast for or against in favor at the meeting held June 11, 2024 for fiscal 2023.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mark Iwicki Chief Executive Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Todd Bazemore President and Chief Operating Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Kim Brazzell Head of Research and Development and Chief Medical Officer | ◇ | ◇ | — | ◇ | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mark Iwicki Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Todd Bazemore President and Chief Operating Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Kim Brazzell Head of Research and Development and Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Mark Iwicki Former Chief Executive Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Todd Bazemore Former Interim Chief Executive Officer, President and Chief Operating Officer Served on an interim basis | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Kim Brazzell Former Head of Research and Development and Chief Medical Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Mary Reumuth Former Chief Financial Officer | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Todd Bazemore Former Interim Chief Executive Officer, President and Chief Operating Officer Departed during or after this year Served on an interim basis | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Kim Brazzell Former Head of Research and Development and Chief Medical Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Mary Reumuth Former Chief Financial Officer Departed during or after this year | ◇ | ◇ | ◇ | ◇ | — | — | ◇ | ◇ |
Mark Iwicki Former Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | ◇ | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Todd Bazemore | Option | ◇ | — | ◇ | 8/28/2035 |
| Option | ◇ | — | ◇ | 1/5/2035 | |
| Option | ◇ | — | ◇ | 6/21/2033 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 3/6/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Mark Iwicki | Option | ◇ | — | ◇ | 6/21/2033 |
| Option | ◇ | — | ◇ | 1/5/2035 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/3/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 6/14/2035 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Mary Reumuth | Option | ◇ | — | ◇ | 1/5/2035 |
| Option | ◇ | — | ◇ | 6/21/2033 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 1/3/2034 | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Andrew I. Koven | ◇ | ◇ | ◇ | — | — | — | ◇ |
Howard B. Rosen | ◇ | ◇ | ◇ | — | — | — | ◇ |
Mark Iwicki | ◇ | ◇ | ◇ | — | — | — | ◇ |
C. Daniel Myers | ◇ | ◇ | ◇ | — | — | — | ◇ |
Marjan Farid | ◇ | ◇ | ◇ | — | — | — | ◇ |
Gregory D. Perry | ◇ | ◇ | ◇ | — | — | — | ◇ |
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2023 | June 11, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 11, 2023 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Mark Iwicki (Former Chief Executive Officer), FY2025 total compensation $906,642 (base salary $111,866) [exec_comp, SEC accession 0001829126-26-010384, filed 2026-09-24]What this page does not include
Everything above is a fact Kala Bio, Inc. disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
175 figures on this page: 173 cited to the filing that reported them, 2 calculated from figures it prints.
173 cited to the filing
2 calculated from the filing
Documents cited
- 0001829126-26-010384EXECUTIVE AND DIRECTOR COMPENSATION
- 0001558370-24-009093The results of the stockholders’ non-binding, advisory vote with respect to the compensation paid to the Company’s named executive officers were as follows: Votes For Votes Against Votes Abstaining Br
- 0001558370-24-006097
- 0001558370-23-011375
- 0001558370-23-002746
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Kala Bio, Inc. executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/KALA (accessed 2026).
Short form: data: Velarion
The paid brief for Kala Bio, Inc.
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Kala Bio, Inc. and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}